Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy

摘要: Cancer remains a leading cause of death in the developed world. Survival rates for patients with common cancers detected at an advanced stage are still low. Only about 10% metastatic colon cancer and 5% pancreatic survive more than 5 years. therapies largely chosen on basis diagnostic categories, all particular tumor type disease receive same treatment. Biological heterogeneity among has long been recognized, but significance these differences respect to course drug responsiveness is just starting be understood. In addition, limited repertoire available drugs made it difficult exploit different treatment strategies.